Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to Buy Rating

Esperion Therapeutics (NASDAQ:ESPR) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday.

ESPR has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Wednesday, October 2nd. Needham & Company LLC dropped their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Esperion Therapeutics has an average rating of “Hold” and a consensus target price of $8.17.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $2.28 on Thursday. The stock’s 50-day moving average is $1.91 and its 200 day moving average is $2.13. Esperion Therapeutics has a 1-year low of $0.87 and a 1-year high of $3.40. The company has a market cap of $447.40 million, a P/E ratio of -2.65 and a beta of 0.96.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The firm had revenue of $73.83 million during the quarter, compared to analysts’ expectations of $51.90 million. On average, analysts anticipate that Esperion Therapeutics will post -0.09 EPS for the current year.

Institutional Trading of Esperion Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. BOKF NA acquired a new position in shares of Esperion Therapeutics in the second quarter valued at about $26,000. Traphagen Investment Advisors LLC acquired a new stake in shares of Esperion Therapeutics during the third quarter worth about $27,000. Xponance Inc. purchased a new stake in Esperion Therapeutics in the second quarter valued at approximately $28,000. CVI Holdings LLC acquired a new position in Esperion Therapeutics in the 1st quarter worth approximately $37,000. Finally, Sivia Capital Partners LLC acquired a new position in Esperion Therapeutics in the 2nd quarter worth approximately $44,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.